Enterprise Value

219.1M

Cash

104.1M

Avg Qtr Burn

-16.16M

Short % of Float

6.98%

Insider Ownership

10.07%

Institutional Own.

54.69%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Interim update

Phase 2

Initiation

PRGN-2012 AdenoVerse™ Details
Recurrent respiratory papillomatosis

Phase 1/2

Update

Phase 1/2

Update

PRGN-3005 UltraCAR-T® Details
Ovarian cancer, Cancer

Phase 1b

Data readout

PRGN-3006 UltraCAR-T® Details
Cancer, Myelodysplastic syndrome, Acute myeloid leukemia

Phase 1b

Data readout

PRGN-3007 UltraCAR-T® Details
Cancer, Solid tumor/s, Blood cancer

Phase 1

Data readout